Cargando…

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation

BACKGROUND: Limited treatment outcome data is available for advanced non-small cell lung cancer (NSCLC) patients with BRAF V600E mutations. In this multicenter study, we describe therapeutic options and survival outcomes for patients with mutated BRAF V600E. METHOD: This was a retrospective study in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Jingjing, Shen, Qian, Li, Yuping, Kalyani, Farhin Shaheed, Liu, Li, Zhou, Jianya, Zhou, Jianying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257040/ https://www.ncbi.nlm.nih.gov/pubmed/35814395 http://dx.doi.org/10.3389/fonc.2022.911303

Ejemplares similares

Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study
por: Qu, Jingjing, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Metanephric stromal tumor with BRAF V600E mutation in an adult patient: Case report and literature review
por: Fan, Yuqian, et al.
Publicado: (2022)

Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases
por: Xia, Rong-Hui, et al.
Publicado: (2021)

Successes and challenges in modeling heterogeneous BRAF(V600E) mutated central nervous system neoplasms
por: Xing, Yao Lulu, et al.
Publicado: (2023)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
por: Di Nunno, Vincenzo, et al.
Publicado: (2023)

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case
por: Yang, Tian, et al.
Publicado: (2021)

Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency
por: Christenson, Eric S., et al.
Publicado: (2023)

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF(V600E) Mutations
por: Su, Yanjun, et al.
Publicado: (2021)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

Diagnostic Efficacy of Ultrasound, Cytology, and BRAF(V600E) Mutation Analysis and Their Combined Use in Thyroid Nodule Screening for Papillary Thyroid Microcarcinoma
por: Du, Jing, et al.
Publicado: (2022)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma
por: Li, Wen, et al.
Publicado: (2023)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF(V600E) mutation responds to dabrafenib and trametinib: a case report and literature review
por: Fang, Ruoxin, et al.
Publicado: (2023)

BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
por: Ahn, Hyo Yeong, et al.
Publicado: (2023)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

Adult classical glioblastoma with a BRAF V600E mutation
por: Takahashi, Yoshinobu, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Mucinous borderline ovarian tumors with BRAF(V600E) mutation may have low risk for progression to invasive carcinomas
por: Ohnishi, Kaori, et al.
Publicado: (2020)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
por: Liu, Chaoyuan, et al.
Publicado: (2022)

BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma
por: Larkin, Sarah Jane, et al.
Publicado: (2014)

Response and resistance to BRAF(V600E) inhibition in gliomas: Roadblocks ahead?
por: Capogiri, Monica, et al.
Publicado: (2023)

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
por: Mu, Yuxin, et al.
Publicado: (2020)

BRAF (AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF (V600E)
por: Da, Rong, et al.
Publicado: (2021)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Shen, Qian, et al.
Publicado: (2021)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum
por: Levinsohn, Jonathan L., et al.
Publicado: (2015)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c0r63bacbqau6r05ka0db0npt8